CTLA4 and melanoma: By analyzing the associations of these targets with immunosuppressive cells and inhibitory immune checkpoints, we previously found that sunitinib treatment was associated with T-cell infiltration and activity and that sunitinib showed a synergistic antitumor effect with an anti-CTLA-4 monoclonal antibody in melanoma through the P62/PD-L1 axis20.